This Article Full Text Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, A.-M. Articles by Gibbons, G. F. Search for Related Content PubMed PubMed Citation Articles by Brown, A.-M. Articles by Gibbons, G. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Animal models of human disease Energy metabolism Type 2 diabetes Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1656.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Insulin Inhibits the Maturation Phase of VLDL Assembly via a Phosphoinositide 3-Kinase—Mediated Event

Anna-Marie Brown; Geoffrey F. Gibbons

From the Metabolic Research Laboratory, Oxford Centre for Diabetes, Endocrinology and Metabolism, Nuffield Department of Clinical Medicine, University of Oxford, Radcliffe Infirmary, Oxford, UK.

Correspondence to Dr G.F. Gibbons, Metabolic Research Laboratory, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK. E-mail geoff.gibbons{at}mrl.ox.ac.uk

Abstract—— LY 294002 (80 µmol/L), an inhibitor of phosphoinositide 3-kinase, was used to investigate the involvement of this enzyme in the insulin-mediated regulation of very low density lipoprotein (VLDL) apolipoprotein B (apoB) output from cultured rat hepatocytes. Newly synthesized apoB was pulse-labeled with [³⁵S]methionine and was then allowed to assemble, via an intermediate precursor stage, into mature VLDL during subsequent chase periods. Brefeldin A (BFA, 0.2 µg/mL) was used to discriminate between the role of insulin in the regulation of the early, compared with the later, events of VLDL assembly, including apoB degradation. Insulin (78 nmol/L), when present during the pulse-labeling and subsequent chase periods, inhibited the secretion of apoB-100 and apoB-48 as VLDL by 53% and 56%, respectively. Degradation of both was concomitantly increased. Secretion of high density lipoprotein apoB, derived from VLDL precursors, was relatively unaffected under these conditions, as was the net synthesis of apoB-100 and apoB-48. The presence of BFA during the pulse-labeling period and subsequent chase period prevented the maturation of VLDL in the insulin-treated and the non–insulin-treated cells. BFA was then removed, allowing the maturation of VLDL to proceed. Removal of insulin at this stage reversed the overall inhibitory effect of insulin. Furthermore, when insulin remained present during this period, the simultaneous presence of LY 294002 also reversed the inhibitory effect of insulin on VLDL apoB output and abolished the increase in apoB degradation. The results suggest that insulin signaling via phosphoinositide 3-kinase inhibited the maturation phase of VLDL assembly by preventing bulk lipid transfer to a VLDL precursor, thus enhancing the degradation of apoB. There was no inhibition of the conversion of newly synthesized apoB into the VLDL precursor form.

Key Words: primary hepatocytes • apolipoprotein B • insulin • phosphoinositide 3-kinase • triacylglycerol

This article has been cited by other articles:

				J. Tsai, R. Zhang, W. Qiu, Q. Su, M. Naples, and K. Adeli Inflammatory NF-{kappa}B activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1287 - G1298. [Abstract] [Full Text] [PDF]

				E. M. Allister, E. E. Mulvihill, P. H. R. Barrett, J. Y. Edwards, L. P. Carter, and M. W. Huff Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor J. Lipid Res., October 1, 2008; 49(10): 2218 - 2229. [Abstract] [Full Text] [PDF]

				N. Anderson and J. Borlak Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357. [Abstract] [Full Text] [PDF]

				N. Morral, H. J. Edenberg, S. R. Witting, J. Altomonte, T. Chu, and M. Brown Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liver J. Lipid Res., July 1, 2007; 48(7): 1499 - 1510. [Abstract] [Full Text] [PDF]

				J. Tsai, W. Qiu, R. Kohen-Avramoglu, and K. Adeli MEK-ERK Inhibition Corrects the Defect in VLDL Assembly in HepG2 Cells: Potential Role of ERK in VLDL-ApoB100 Particle Assembly Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 211 - 218. [Abstract] [Full Text] [PDF]

				M. A. M. den Boer, P. J. Voshol, F. Kuipers, J. A. Romijn, and L. M. Havekes Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1360 - E1364. [Abstract] [Full Text] [PDF]

				D. V. Chirieac, N. O. Davidson, C. E. Sparks, and J. D. Sparks PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G382 - G388. [Abstract] [Full Text] [PDF]

				L. Duvillard, E. Florentin, S. Baillot-Rudoni, M.-L. Lalanne-Mistrich, A. Brun-Pacaud, J.-M. Petit, J.-M. Brun, P. Gambert, and B. Verges Comparison of Apolipoprotein B100 Metabolism between Continuous Subcutaneous and Intraperitoneal Insulin Therapy in Type 1 Diabetes J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5761 - 5764. [Abstract] [Full Text] [PDF]

				A. Grefhorst, J. Hoekstra, T. G. J. Derks, D. M. Ouwens, J. F. W. Baller, R. Havinga, L. M. Havekes, J. A. Romijn, and F. Kuipers Acute hepatic steatosis in mice by blocking {beta}-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G592 - G598. [Abstract] [Full Text] [PDF]

				M. Adiels, J. Boren, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S.-O. Olofsson, C. Packard, and M.-R. Taskinen Overproduction of VLDL1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1697 - 1703. [Abstract] [Full Text] [PDF]

				W. Qiu, R. K. Avramoglu, N. Dube, T. M. Chong, M. Naples, C. Au, K. G. Sidiropoulos, G. F. Lewis, J. S. Cohn, M. L. Tremblay, et al. Hepatic PTP-1B Expression Regulates the Assembly and Secretion of Apolipoprotein B-Containing Lipoproteins: Evidence From Protein Tyrosine Phosphatase-1B Overexpression, Knockout, and RNAi Studies Diabetes, December 1, 2004; 53(12): 3057 - 3066. [Abstract] [Full Text] [PDF]

				N. M. Borradaile, L. E. de Dreu, and M. W. Huff Inhibition of Net HepG2 Cell Apolipoprotein B Secretion by the Citrus Flavonoid Naringenin Involves Activation of Phosphatidylinositol 3-Kinase, Independent of Insulin Receptor Substrate-1 Phosphorylation Diabetes, October 1, 2003; 52(10): 2554 - 2561. [Abstract] [Full Text] [PDF]